Psychosis

🔍 Three Things You Likely Didn’t Know About Psychosis

1. Psychosis is not a diagnosis — it is a syndrome with dozens of possible causes. Hearing voices or holding fixed false beliefs tells you something is wrong — but not what is wrong. Psychosis can arise from schizophrenia, bipolar disorder, autoimmune encephalitis, brain tumors, infections, sleep deprivation, and many other causes. Treating psychosis without identifying its cause is like treating a fever without looking for the infection.

2. A treatable autoimmune condition can look exactly like schizophrenia — and it was only discovered in 2007. Anti-NMDA receptor encephalitis causes the immune system to attack the brain, producing hallucinations, delusions, and seizures. Before its discovery, many patients were almost certainly misdiagnosed with primary psychiatric illness. With prompt immunotherapy — typically corticosteroids, IVIG, or plasma exchange, with rituximab for refractory cases — approximately 75–80% of patients achieve substantial functional recovery, though the process is often slow and ongoing management may be needed to prevent relapse (Nguyen & Wang, 2023).

3. Every week of untreated psychosis makes long-term outcomes measurably worse. The first few years after psychosis onset represent a critical window: the brain is most responsive to intervention and most vulnerable to the effects of sustained psychosis (Penttila et al., 2014). That is why early identification is not merely preferable but urgent.

---

📋 Overview

Psychosis is a clinical syndrome characterized by a significant loss of contact with shared reality. Its core features include:

• Hallucinations — sensory perceptions in the absence of external stimuli. Auditory hallucinations (hearing voices) are the most common in psychiatric psychosis, while visual hallucinations are more characteristic of organic or substance-related causes — a distinction with important diagnostic implications.
• Delusions — fixed, false beliefs held with conviction despite contradictory evidence. These may be persecutory, grandiose, referential (believing that random events carry special personal meaning), bizarre, or somatic in content.
• Disorganized thinking and speech — derailment, tangentiality, loose associations, word salad, or incoherence that reflects a fundamental disruption in the organization of thought.
• Grossly disorganized or catatonic behavior — unpredictable agitation, inappropriate affect, bizarre behavior, or catatonic features (stupor, posturing, mutism, waxy flexibility).

Psychosis is not rare — approximately 3% of the population will experience at least one psychotic episode during their lifetime, most commonly in late adolescence and early adulthood.

What makes psychosis clinically urgent is the breadth of its differential diagnosis. The same presentation can reflect a primary psychiatric illness, a neurological emergency, a systemic medical condition, or a substance effect — and the treatment for each is radically different.

---

🔀 Causes and Categories

The causes of psychosis are diverse. A systematic approach to differential diagnosis is the most important clinical skill in evaluating a patient with new-onset psychotic symptoms.

Primary Psychiatric Causes

• Schizophrenia spectrum disorders — schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder
• Mood disorders with psychotic features — bipolar I disorder (manic or depressive episodes with psychotic features), major depressive disorder with psychotic features
• Other — psychotic features in the context of severe PTSD, borderline personality disorder (transient, stress-related), or obsessive-compulsive disorder with absent insight

Substance-Related Causes

• Intoxication — cannabis (particularly high-THC strains), methamphetamine, cocaine, hallucinogens (LSD, psilocybin, PCP, ketamine), synthetic cannabinoids, MDMA
• Withdrawal — alcohol (delirium tremens), benzodiazepines, barbiturates
• Medication-induced — corticosteroids, dopaminergic agents (used in Parkinson’s disease), certain antimalarials, anticholinergic medications, and — rarely — some antidepressants

Medical and Neurological Causes

• Autoimmune — anti-NMDA receptor encephalitis, systemic lupus erythematosus (cerebral lupus), multiple sclerosis, Hashimoto’s encephalopathy
• Neurological — temporal lobe epilepsy, brain tumors, stroke, traumatic brain injury, neurodegenerative disease (Lewy body dementia, Huntington’s, frontotemporal dementia)
• Infectious — neurosyphilis, HIV encephalopathy, herpes simplex encephalitis, prion disease
• Metabolic and endocrine — thyroid disorders, adrenal disorders (Cushing’s syndrome), porphyria, Wilson’s disease, hepatic or uremic encephalopathy, severe electrolyte disturbances
• Other — severe sleep deprivation, postpartum psychosis (a psychiatric emergency that may have autoimmune or hormonal underpinnings), delirium of any cause

This list is not exhaustive — and that is precisely the point. The evaluation of psychosis is a diagnostic exercise that demands medical thoroughness, not premature diagnostic closure.

---

🩺 Diagnosis

The evaluation of psychosis — particularly first-episode psychosis — is one of the most high-stakes diagnostic challenges in medicine: characterize the psychotic symptoms, identify the underlying cause, and initiate appropriate treatment as rapidly as possible.

A comprehensive first-episode psychosis workup typically includes:

• Detailed psychiatric history — features worth exploring often include symptom onset, prodromal features, timeline, family psychiatric history, developmental history, premorbid functioning, prior substance use, and medication history. The presence of mood symptoms and their temporal relationship to psychotic symptoms is critical for differentiating between schizophrenia spectrum disorders and mood disorders with psychotic features.
• Medical history and physical examination — including neurological examination. New-onset psychosis in the context of fever, seizures, headache, movement abnormalities, or rapid cognitive decline should raise immediate concern for a medical etiology.
• Laboratory studies — complete blood count, comprehensive metabolic panel, thyroid function, vitamin B12, folate, inflammatory markers (ESR, CRP), urinalysis, toxicology screen, HIV and syphilis testing. Additional studies — including autoimmune panels (anti-NMDA receptor antibodies, ANA, anti-thyroid antibodies), copper and ceruloplasmin (Wilson’s disease screening), and porphyria screening — are indicated based on clinical suspicion.
• Neuroimaging — MRI of the brain is recommended for all first-episode psychosis presentations to exclude structural lesions, demyelinating disease, or other abnormalities.
• Electroencephalography (EEG) — indicated when seizures, encephalitis, or delirium are suspected. Temporal lobe epilepsy, in particular, can produce psychotic symptoms that mimic primary psychiatric illness.
• Lumbar puncture — when autoimmune or infectious encephalitis is suspected, CSF analysis is essential and may be diagnostic.
• Standardized psychiatric assessment — structured severity ratings support diagnostic clarity and treatment-response tracking.

The single most consequential error in psychosis evaluation is premature diagnostic closure — labeling a patient with schizophrenia based on a brief encounter without adequately ruling out medical causes. A treatable autoimmune encephalitis misdiagnosed as schizophrenia is not merely a missed diagnosis; it is a potentially life-threatening error.

---

💊 Treatment Approach

Treatment of psychosis depends entirely on its underlying cause — which is why diagnostic precision is paramount.

Psychotherapy

Psychotherapy is a critical component of care for psychosis, regardless of etiology. Cognitive-behavioral therapy for psychosis (CBTp) has evidence for reducing the distress and behavioral impact of hallucinations and delusions. Alongside CBTp, acceptance and commitment therapy (ACT) has shown particular promise for psychosis — helping patients reduce struggle with distressing internal experiences and re-engage with valued life activities even in the presence of ongoing symptoms. Compassion-focused therapy (CFT) addresses the shame and self-stigma that often accompany psychotic experiences and can be more debilitating than the symptoms themselves.

For first-episode psychosis, early intervention programs combining psychotherapy, low-dose pharmacotherapy, family support, and vocational assistance have demonstrated superior outcomes compared to standard care.

Family psychoeducation is especially important in first-episode psychosis, where families are often frightened and unsure how to help.

Medication and Neuromodulation

For primary psychiatric psychosis, antipsychotic medications, also known as dopaminergic modulators or antagonists are typically the foundational pharmacological intervention. These agents modulate dopamine signaling — primarily through dopamine D2 receptor activity — and are effective in reducing positive symptoms (hallucinations, delusions, disorganized thinking) in the majority of patients.

When psychosis occurs in the context of a mood disorder, treatment must address the mood episode as well. Mood-stabilizing agents, certain antidepressant classes, and combination strategies are selected based on whether the underlying mood disorder is bipolar or unipolar in nature.

For substance-induced psychosis, the primary intervention is cessation of the offending substance, with supportive antipsychotic treatment as needed during the acute phase. Many patients recover fully once the substance is cleared but this process may take months. A subset — particularly those with cannabis- or methamphetamine-induced psychosis — may transition to a primary psychotic disorder and require ongoing monitoring.

For medical causes of psychosis, treatment is directed at the underlying condition — immunotherapy for autoimmune encephalitis, antimicrobials for infection, correction of metabolic derangements, surgical or oncological management for CNS lesions. Antipsychotic medications may provide symptomatic relief in the interim, but they do not address the root cause.

Neuromodulation, including TMS, tDCS, and ECT, are options worth considering in treatment-resistant cases. ECT, in particular, is an important alternative for treatment-resistant psychosis, as well as for catatonic presentations and severe psychotic depression. However, it comes with significant side effects cognitively and should be assessed carefully in terms of its benefits versus risks.

Integrative and Lifestyle Approaches

Targeted nutritional interventions, anti-inflammatory strategies, exercise protocols, and sleep optimization have each shown signals of benefit as adjuncts to standard treatment. The metabolic consequences of many antipsychotic medications make proactive lifestyle management clinically necessary. These interventions are most effective when individualized based on the patient’s biology, medication regimen, and recovery goals.

---

🌱 Outlook

For first-episode psychosis due to primary psychiatric illness, early intervention is associated with better outcomes — including higher remission rates, better functional recovery, and reduced long-term disability. For medical causes of psychosis, many are partially or fully reversible when identified and treated promptly.

For substance-induced psychosis, outcomes are closely tied to substance cessation. Long-term follow-up studies show that 20–30% of individuals initially diagnosed with substance-induced psychosis eventually receive a diagnosis of a primary psychotic disorder, highlighting the importance of continued monitoring even after apparent recovery.

Psychosis does not define a person. With accurate diagnosis, early treatment, and sustained support, meaningful recovery is not only possible but expected.

---

🏥 How to Get Better

At our psychiatry practice, we treat psychosis with an evidence-based, multimodal approach — combining precision medication with specialized psychotherapy, and integrating neuromodulation, targeted supplements, stress management, and lifestyle optimization for patients who want a comprehensive treatment plan.

Ready to get started? Schedule an intake appointment — a thorough evaluation where we clarify your diagnosis, map out your treatment plan, and get everything moving: medication orders, therapy, supplements, and nutrition. Your care begins the same day, not weeks later.

Schedule Your Intake

We offer statewide telehealth services in California and Florida, with in-person appointments available in Los Angeles and Miami. We also regularly assist international patients due to our fluency in Portuguese, Spanish, and Farsi.

---

📚 References

1. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). American Psychiatric Publishing.
2. Maijer, K., Begemann, M. J. H., Palmen, S. J. M. C., et al. (2018). Auditory hallucinations across the lifespan: A systematic review and meta-analysis. Psychological Medicine, 48(6), 879–888.
3. Dalmau, J., Gleichman, A. J., Hughes, E. G., et al. (2008). Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. The Lancet Neurology, 7(12), 1091–1098.
4. Penttila, M., Jaaskelainen, E., Hirvonen, N., Isohanni, M., & Miettunen, J. (2014). Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry, 205(2), 88–94.
5. Correll, C. U., Galling, B., Pawar, A., et al. (2018). Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry, 75(6), 555–565.
6. Fusar-Poli, P., McGorry, P. D., & Kane, J. M. (2017). Improving outcomes of first-episode psychosis: an overview. World Psychiatry, 16(3), 251–265.
7. Freudenreich, O., Schulz, S. C., & Goff, D. C. (2009). Initial medical work-up of first-episode psychosis: a conceptual review. Early Intervention in Psychiatry, 3(1), 10–18.
8. Kapur, S. (2003). Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry, 160(1), 13–23.
9. Morrison, A. P., Turkington, D., Pyle, M., et al. (2014). Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. The Lancet, 383(9926), 1395–1403.
10. Murrie, B., Lappin, J., Large, M., & Sara, G. (2020). Transition of substance-induced, brief, and atypical psychoses to schizophrenia: a systematic review and meta-analysis. Schizophrenia Bulletin, 46(3), 505–516.
11. Pollak, T. A., Lennox, B. R., Muller, S., et al. (2020). Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. The Lancet Psychiatry, 7(1), 93–108.
12. Nguyen, L., & Wang, C. (2023). Anti-NMDA receptor autoimmune encephalitis: diagnosis and management strategies. International Journal of General Medicine, 16, 7–21.